Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04111705
Title Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Intergroupe Francophone de Cancerologie Thoracique
Indications

lung non-small cell carcinoma

Therapies

Lorlatinib

Age Groups: senior | adult
Covered Countries FRA

Additional content available in CKB BOOST